Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
ACMG Issues DTC Genetic-Testing Guidelines; SACGHS Cites Role of Professional Societies
May 07, 2008
The ACMG’s five-point Policy Statement on Direct-to-Consumer Genetic Testing recommends that any genetic-testing protocol should employ “knowledgeable” health-care professionals to order and interpret the tests; inform consumers about what a test can and cannot determine about their health; present the scientific evidence upon which a test is based; perform the test in an accredited lab; and address consumers' privacy concerns.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- NIH Awards Lucigen $2.8M SBIR Grant for POC Influenza Test
May 23, 2012 / GenomeWeb Daily News - Genentech Takes Personalized Medicine Approach in Pursuing Amyloid Hypothesis for Alzheimer's Drug
May 23, 2012 / Pharmacogenomics Reporter - Agilent to Strengthen Personalized Rx Foothold with $2.2B Dako Acquisition
May 23, 2012 / Pharmacogenomics Reporter - NIH Study Finds DTC Genetic Risk Info Doesn't Increase Patients' Use of Healthcare Services
May 23, 2012 / Pharmacogenomics Reporter - Vertex Says CF Patients with Double F508del Mutation Showing Improvement in VX-809/Kalydeco Trial
May 23, 2012 / Pharmacogenomics Reporter